Boehringer Ingelheim: Restless Legs Syndrome trials

The registry lists 21 Restless Legs Syndrome studies with Boehringer Ingelheim as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 2 3Phase 3 6Phase 4 4No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)CompletedNCT02231918Phase 2Results posted
• Survey on Long-Term Use of BI-Sifrol® Tablets in Patients With Restless Legs SyndromeCompletedNCT01174459Results posted
• Safety and Effect of Mirapex(Pramipexole) Tablet Among Korean RLSCompletedNCT01170091Results posted
• Non-interventional Observational Study on the Influence of Pramipexole on Sensory Symptoms of Restless Legs Syndrome (RLS)CompletedNCT00887289Results posted
• Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs SyndromeCompletedNCT00721279Results posted
• Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)CompletedNCT00654498Phase 3Results posted
• Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)CompletedNCT00472199Phase 4Results posted
• A Randomised, Comparing Fixed Doses of Pramipexole to Investigate the Efficacy and Safety in Patients With RLS.CompletedNCT00390689Phase 3Results posted
• Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)CompletedNCT02248155
• Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)CompletedNCT02248142
• Cross-Sectional Study: Prevalence of Restless Legs Syndrome in Patients With Unpleasant Sensations of the LegsCompletedNCT00557258
• Non-interventional Observational Study of Pramipexole in Restless Legs Syndrome: Impact on Quality of LifeCompletedNCT00539461
• A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLSCompletedNCT00375284Phase 4
• Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood DisturbancesCompletedNCT00356096Phase 4
• A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLSCompletedNCT00349531Phase 4
• Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) PatientsCompletedNCT00275457Phase 3
• Dose Finding Study of Pramipexole (Sifrol) in Patients With Idiopathic Restless Legs Syndrome (RLS)CompletedNCT00239486Phase 2
• Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs SyndromeCompletedNCT00152997Phase 2
• A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)CompletedNCT00152958Phase 3
• Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs SyndromeCompletedNCT00144209Phase 3
• Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)CompletedNCT00133198Phase 3